• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Iranian Journal of Pharmaceutical Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 18 (2019)
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Supplement
Issue Issue 1
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Khodadad, K., khosravi, A., Esfahani-Monfared, Z., Karimi, S., Seifi, S. (2014). Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study. Iranian Journal of Pharmaceutical Research, 13(2), 575-581. doi: 10.22037/ijpr.2014.1492
Kian Khodadad; adnan khosravi; Zahra Esfahani-Monfared; Shirin Karimi; Sharare Seifi. "Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study". Iranian Journal of Pharmaceutical Research, 13, 2, 2014, 575-581. doi: 10.22037/ijpr.2014.1492
Khodadad, K., khosravi, A., Esfahani-Monfared, Z., Karimi, S., Seifi, S. (2014). 'Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study', Iranian Journal of Pharmaceutical Research, 13(2), pp. 575-581. doi: 10.22037/ijpr.2014.1492
Khodadad, K., khosravi, A., Esfahani-Monfared, Z., Karimi, S., Seifi, S. Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study. Iranian Journal of Pharmaceutical Research, 2014; 13(2): 575-581. doi: 10.22037/ijpr.2014.1492

Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study

Article 24, Volume 13, Issue 2, Spring 2014, Page 575-581  XML PDF (984.08 K)
Document Type: Research article
DOI: 10.22037/ijpr.2014.1492
Authors
Kian Khodadad1; adnan khosravi email 2; Zahra Esfahani-Monfared3; Shirin Karimi4; Sharare Seifi5
1Assistant Professor of Internal Medicine, Hematology and Medical Oncology, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease
2Assistant Professor of Internal Medicine, Hematology and Medical Oncology
3General Physician, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Associate Professor of Pathology, Pathology Department, Mycobacteriology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Assistant Professor of Internal Medicine, Hematology and Medical Oncology, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease NRITLD, Masih Daneshvari Hospital,
Abstract
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice.
Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative Oncology Group performance status of 0 to 2. They were randomly assigned by stratified blocks to receive Docetaxel/Cisplatin (DC, n=50) on day 1 or Paclitaxel/Carboplatin AUC 5 (PC, n=50) on day 1, every 3 weeks for up to six cycles. Primary end point was progression free survival (PFS); secondary end points were objective response rate, overall survival (OS) and toxicity. The administered dosage could be modified according to clinician’s discretion for each individual patient.
Results: PFS was similar between DC and PC arms (4.5±0.3 v 4.6±1.8 months, respectively; HR= 1.337; 95% CI: 0.874 to 2.046, P= 0.181). Although median overall survival for DC arm was longer (17.2±4.4 m) than PC arm (10.6±0.7 m) but was not statistically significant (P=0.300). The 1-year survival rates were in favor of DC arm (53.1% v 37.9%). Objective response rates were similar in both groups. In our study, hematologic toxicity and neuropathy were more frequent in DC and PC arms, respectively.
Conclusion: In our study two commonly used regimens of DC and PC showed statistically similar outcomes in terms of PFS and OS, albeit numerically results of OS and 1-year survival were in favor of DC arm.
Keywords
docetaxel; Paclitaxel; Non-Small Cell; Lung Cancer
Main Subjects
Medicinal chemistry
Statistics
Article View: 3,477
PDF Download: 4,989
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.